
Please try another search
Telix Pharmaceuticals Limited is a radiopharmaceutical company focused on the development of diagnostic and therapeutic radiopharmaceuticals products using Molecularly Targeted Radiation (MTR) to treat cancer. In MTR therapy, a radionuclide is attached to a targeting agent such as a small molecule or antibody. This targeting agent specifically binds to tumors and delivers a radioactive payload in a selective way. The radioactive payload can either be diagnostic (for imaging) or therapeutic, or both. The Company’s lead programs include TLX591-CDx (Illuccix) / TLX591 for diagnosis and treatment of metastatic castrate-resistant prostate cancer, TLX250-CDx/TLX250 for diagnosis and treatment of renal (kidney) cancer, TLX101-CDx / TLX101 for diagnosis and treatment of glioblastoma (brain cancer), and TLX66-CDx (Scintimun) / TLX66 for the treatment of bone marrow conditioning and rare diseases.
Name | Age | Since | Title |
---|---|---|---|
Harry Kevin McCann | 80 | 2017 | Independent Non-Executive Chairman |
Klaus Kopka | - | - | Member of the Scientific Advisory Board |
Samuel Samnick | - | - | Member of the Scientific Advisory Board |
Rodney W. Hicks | - | - | Member of the Scientific Advisory Board |
Jean-François Chatal | - | - | Member of the Scientific Advisory Board |
Jason Lewis | - | - | Member of the Scientific Advisory Board |
Tiffany P. Olson | 63 | 2022 | Independent Non-Executive Director |
Chaitanya R. Divgi | - | - | Member of the Scientific Advisory Board |
Frederik L. Giesel | - | 2020 | Member of Scientific Advisory Board |
Richard Zimmermann | - | 2017 | Member of Scientific Advisory Board |
Neil H. Bander | - | - | Member of the Scientific Advisory Board |
Richard Baum | - | - | Member of the Scientific Advisory Board |
Stefano Fanti | - | 2019 | Scientific Advisor |
Mark Alexander Nelson | - | 2017 | Independent Non-Executive Director |
Andreas Kluge | - | 2017 | Chief Medical Advisor & Director (Leave of Absence) |
Jann E. Skinner | 65 | 2018 | Independent Non-Executive Director |
Christian P. Behrenbruch | 48 | 2017 | Co-Founder, MD, Group CEO & Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review